Nursing facility
NPI deactivated
Northeast MT Health Services
Northeast MT Health Services was paid $2.24M by Medicaid between Jan 2018 and Dec 2024, across 117 billing codes. Its largest line is A0429, emergency ambulance ride, basic life support — 57% of everything it billed.
33Billing provider infoNORTHEAST MT HEALTH SERVICES
WOLF POINT, MT 59201
WOLF POINT, MT 59201
33aNPI1821016536assigned 07/18/2006
33bProvider typeSkilled Nursing Facility
28Total paid$2.24M
24GClaims145,781
24DCodes billed117
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Skilled Nursing Facility providers in Montana
Rank by total paid#1 of 10
Median peer was paid$49K
This provider vs. median45×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,341 | $336K | |
| 2019 | 21,189 | $323K | |
| 2020 | 22,840 | $344K | |
| 2021 | 27,829 | $393K | |
| 2022 | 21,656 | $332K | |
| 2023 | 18,969 | $299K | |
| 2024incomplete | 12,957 | $208K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 57% | 5,300 | 3,925 | $1.27M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 15% | 1,003 | 895 | $342K |
| A0380 | Bls mileage (per mile) | 11% | 3,403 | 2,747 | $242K |
| A0382 | Bls routine disposable supplies | 5.5% | 2,048 | 1,768 | $123K |
| A0390 | Als mileage (per mile) | 2.9% | 475 | 443 | $66K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.5% | 5,301 | 4,880 | $34K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.3% | 4,374 | 4,000 | $29K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 3,416 | 3,062 | $21K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 2,655 | 2,298 | $10K |
| 80053 | Comprehensive metabolic panel | <1% | 9,981 | 8,040 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,367 | 2,017 | $8K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,501 | 2,324 | $7K |
105 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,179 | $6K |
| 87631 | <1% | 161 | $6K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,147 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,310 | $5K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,591 | $5K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,813 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,129 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,335 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,296 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 418 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,330 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,722 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,571 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,677 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 655 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,364 | $1K |
| 87077 | <1% | 2,127 | $1K | |
| 83605 | <1% | 1,605 | $1K | |
| 80305 | <1% | 4,067 | $1K | |
| 87070 | <1% | 1,527 | $1K | |
| 87186 | <1% | 1,632 | $1K | |
| 87634 | <1% | 345 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,399 | $994.93 |
| 81001 | <1% | 4,756 | $935.71 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,656 | $913.93 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,301 | $852.94 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,383 | $751.04 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 144 | $739.35 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,707 | $503.15 |
| 81025 | <1% | 772 | $404.36 | |
| 87040 | <1% | 1,035 | $382.05 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 94 | $357.97 |
| 85610 | <1% | 1,856 | $322.19 | |
| 82948 | <1% | 421 | $308.14 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 438 | $306.70 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,430 | $274.50 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 824 | $263.89 |
| 80061 | Lipid panel | <1% | 376 | $247.73 |
| 73610 | <1% | 27 | $222.97 | |
| 86140 | <1% | 448 | $201.60 | |
| 81003 | <1% | 375 | $177.72 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 514 | $174.91 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 529 | $174.17 |
| 85027 | <1% | 1,118 | $168.07 | |
| 82805 | <1% | 317 | $160.20 | |
| 87205 | <1% | 535 | $153.67 | |
| 82607 | <1% | 160 | $146.70 | |
| 85730 | <1% | 861 | $132.07 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $117.67 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,017 | $113.39 |
| 87510 | <1% | 337 | $108.90 | |
| 87480 | <1% | 337 | $108.90 | |
| 82077 | <1% | 320 | $108.22 | |
| 82746 | <1% | 129 | $106.87 | |
| 86900 | <1% | 318 | $103.72 | |
| 83690 | <1% | 599 | $96.75 | |
| 86850 | <1% | 310 | $94.27 | |
| 87660 | <1% | 337 | $87.30 | |
| 84484 | <1% | 760 | $85.96 | |
| 85007 | <1% | 549 | $80.32 | |
| 86762 | <1% | 14 | $72.00 | |
| 85651 | <1% | 75 | $41.17 | |
| 86901 | <1% | 307 | $16.19 | |
| 71045 | Radiologic examination, chest; single view | 0% | 669 | $0.00 |
| 85652 | 0% | 190 | $0.00 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 231 | $0.00 |
| 83615 | 0% | 91 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 136 | $0.00 |
| 83735 | 0% | 777 | $0.00 | |
| 96376 | 0% | 31 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 18 | $0.00 |
| 94680 | 0% | 112 | $0.00 | |
| 82150 | 0% | 206 | $0.00 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 0% | 55 | $0.00 |
| 86920 | 0% | 31 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 74 | $0.00 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 0% | 154 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 25 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 292 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 81 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 19 | $0.00 |
| 74022 | 0% | 15 | $0.00 | |
| 90686 | 0% | 14 | $0.00 | |
| 74019 | 0% | 15 | $0.00 | |
| 80320 | 0% | 39 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| J3490 | Unclassified drugs | 0% | 31 | $0.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 15 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 29 | $0.00 |
| 85379 | 0% | 14 | $0.00 | |
| 83880 | 0% | 15 | $0.00 | |
| 97161 | 0% | 32 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 282 | $0.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 1,681 | $0.00 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 26 | $0.00 |
| 84439 | 0% | 153 | $0.00 | |
| 96367 | 0% | 164 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 77 | $0.00 |
| 82140 | 0% | 36 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 34 | $0.00 |
| 82570 | 0% | 27 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 99 | $0.00 |
| 73130 | 0% | 12 | $0.00 | |
| 90715 | 0% | 25 | $0.00 | |
| 84481 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOVERSLAND, MARY (BUSINESS OFFICE DIRECTOR)